Monogram Technologies Submits 510(k) Application for mBôs TKA System Clearance

August 8, 2024 8:00 AM

Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for the Company's mBôs TKA System. The application was submitted on July 19, 2024, and passed the FDA Administrative Review. An FDA decision is expected...

Read more

Hear AtLast and A.C.T. Investment Group Sign Agreement for Purchase of Income Properties In North America

August 8, 2024 8:00 AM

MIAMI, FL / ACCESSWIRE / August 8, 2024 / Hear AtLast (OTC PINK:HRAL) is excited to announce its new venture with A.C.T. Investments to engage to purchase income properties across North America. This will be an opportune time to invest in residential and proposed land development of high rise residential.A.C.T. Investments is a group of investors who are developing and purchasing homes for low income families surrounding Rochester. HRAL and...

Read more

Registration is Now Open for Tribe Public’s Webinar Event "Diabetes Care Innovator Modular Medical Takes Next Steps" Featuring Modular Medical CEO on Friday, August 9, 2024

August 8, 2024 8:00 AM

The global diabetes care market, valued at $18.9 billion in 2023, is projected to reach $35.8 billion by 2028The insulin pump segment is expected to grow from $5.26 billion to $21.65 billion by 2032Discover how Modular Medical is accelerating the development of technology to empower the whole diabetes community with MODD1Meet with Modular Medical CEO Jeb BesserSAN DIEGO, CA / ACCESSWIRE / August 8, 2024 / Modular Medical, Inc. (NASDAQ:MODD)...

Read more

Xtant Medical Announces $5.0 Million Private Placement

August 8, 2024 7:20 AM

Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with an existing institutional investor to sell shares of its common stock in a private placement. The Company agreed to issue an aggregate of 7,812,500 shares of common stock at a purchase price of $0.64 per share, resulting...

Read more

Xtant Medical to Host Second Quarter 2024 Financial Results Earnings Conference call on August 9, 2024

August 8, 2024 7:10 AM

Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 8, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call...

Read more

Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%

August 8, 2024 7:05 AM

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024.Second Quarter 2024 Financial HighlightsRevenue of $29.9 million, up 48%, compared to the prior year quarterGross margin of 62.1%, up 50 basis points, compared to the prior year quarterNet loss of $3.9...

Read more

Bionoid Pharma, Inc. Acquires AI Maverick Intel

August 8, 2024 7:00 AM

Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) announces the signing of a definitive agreement with Stronghold Media Group Corp. ("Stronghold") to acquire the intellectual property rights of AI Maverick Intel, a cutting-edge technology set to revolutionize customer acquisition by enabling companies to find, engage, nurture, and acquire their ideal audiences at high velocity and automated scale. Revolutionizing Audience Engagement with AI...

Read more

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

August 8, 2024 6:30 AM

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program and strategy in this letter to investors.NanoViricides is developing a unique direct-acting antiviral drug that mimics the host cell and thereby is designed to disable the virus particle from infecting the cell. Our first clinical stage drug, NV-387 is designed to mimic...

Read more

SphingoTec Closes €5M Series C to Accelerate Market Development and Financial Growth with Innovative Biomarkers

August 8, 2024 4:30 AM

Diagnostics company SphingoTec GmbH ("SphingoTec") announces the successful closing of a Series C financing round. The raised capital will allow the company to reach profitability through sustained and strategic commercialization of its products. This includes supporting market development, out-licensing activities, and close collaboration with licensees. SphingoTec aims for global expansion, including entry into the US market. The lead...

Read more

NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines

August 8, 2024 2:40 AM

NEC Bio Therapeutics and AGC Biologics have announced a partnership to advance the production of NECVAX-NEO1, an orally delivered, bacteria-based DNA vaccine designed to target patient-specific tumor neoantigens. This important and promising collaboration aims to enhance the production of personalized cancer treatments by leveraging the biotechnology strengths of both companies.Advancing Personalized Cancer TreatmentNEC Bio Therapeutics, a...

Read more

Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb

August 8, 2024 1:50 AM

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research.Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify...

Read more

Kuros Biosciences Reports First Half of 2024 Results

August 8, 2024 1:30 AM

Financial HighlightsDirect MagnetOs™ sales increased by 159% to CHF 31.6 million from CHF 12.2 million in H1 2023; this corresponds to a sequential increase of 62% or CHF 12.1 million over H2 2023Total Kuros Medical Devices segment sales increased 148% to CHF 31.8 million from CHF 12.9 millionKuros Medical Devices segment EBITDA increased 287% to CHF 8.6 million in H1 2024 compared to CHF 2.2 million in H1 2023, representing an EBITDA margin of...

Read more

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024

August 7, 2024 4:05 PM

Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / August 7, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2024.Second Quarter HighlightsNet revenues of $182.4 million for the second quarterGAAP net income of $37.9 million, or $0.73 per share, for the second quarterAdjusted non-GAAP net...

Read more

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

August 7, 2024 4:05 PM

Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW)("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2024."We are excited to have enrolled over 50% of patients in our DMT310 Phase 3 STAR-1 trial, and we look forward to the second half of 2024...

Read more

Health eCareers and Society of Critical Care Medicine Announce New Collaboration  

August 7, 2024 12:45 PM

This collaboration provides career opportunities for critical care professionals by creating connections with employers seeking these highly sought-after and specialized skills.NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Health eCareers, North America's leading recruitment and career network serving healthcare professionals, employers and associations, announced a new collaboration with the Society of Critical Care Medicine (SCCM) that improves...

Read more

NCQA Updates 2025 Credentialing Product Suite

August 7, 2024 12:00 PM

Updates ensure consistent, effective and diligent qualification verification processWASHINGTON, DC / ACCESSWIRE / August 7, 2024 / The National Committee for Quality Assurance (NCQA) announced updates to its Credentialing Product Suite, which provides a framework for healthcare organizations to implement industry best practices that help them accurately and efficiently credential and recredential licensed health care professionals to ensure an...

Read more

Hedden & Gunn Plastic Surgery Welcomes New Facial Plastic Surgeon, Dr. Beau Vandiver, Expanding Team Excellence

August 7, 2024 10:00 AM

BIRMINGHAM, AL / ACCESSWIRE / August 7, 2024 / Hedden & Gunn Plastic Surgery, a distinguished member of Ascend Aesthetic Partners, announces the appointment of Dr. Beau Vandiver as its newest facial plastic surgeon, effective July 31, 2024. Dr. Vandiver joins the esteemed practice, bringing a wealth of expertise and a dedication to advancing patient care in the Birmingham, Alabama area. Dr. Vandiver obtained his Doctor of Medicine degree from...

Read more

Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

August 7, 2024 8:00 AM

Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same...

Read more

Modular Medical Initiates Transfer of Manufacturing Operations to Phillips Medisize

August 7, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch the next generation of easy-to-use, prescribe and live with affordable insulin pump technology, today announced it has begun the transfer of its pilot line manufacturing operations to a Phillips Medisize manufacturing site in Queretaro, Mexico.Phillips Medisize,...

Read more

Evotec SE Reports First Half-year 2024 Results on 14 August 2024

August 7, 2024 7:15 AM

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024.The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.Webcast detailsDate: Wednesday, 14 August 2024Time: 2.00 pm CEST (01.00 pm BST, 08.00 am EDT)To join...

Read more